From COVID to chronic infections to cancer, stem cell-derived extracellular vesicles (EVs) have the potential to change the landscape of regenerative medicine and the treatment of inflammatory conditions. Though still in early-stage research, work with EVs in the field already appears to hold great promise.
Based on studies with similar or sometimes potentially better therapeutic capacity as compared to stem cells, EVs also offer the advantages of being non-immunogenic, able to bypass the blood-brain barrier, and their tropism.
But in order to make these potential therapies accessible, there is a need for optimized, large-scale EV production methods. Corning offers a line of products designed for large-scale cell culture applications. From the Corning® CellCube® and Corning CellSTACK® cell culture chambers, to the Corning HYPERFlask® and HYPERStack® vessels, these products allow the culture of a high volume of cells in a small footprint.